Only 22 sleeps until Christmas, and somehow we’ve already reached the final Voices of Innovation episode of 2025.
For this closing conversation of the year, I wanted to bring you the perspective of someone who has lived both sides of the industry: Massimo Mineo, BSc, MSc, a biotech entrepreneur who spent many years in senior leadership roles within large pharma before taking the leap into the slightly riskier (but let’s be honest — far more exciting) world of early-stage biotech.
Massimo is the CEO and co-founder of Neurolieve Biosciences Ltd, a company developing treatments for neuropathic pain. Alongside this, he’s actively involved in scouting and supporting innovative drug-development projects, using his deep commercial and pharma experience to guide emerging ventures.
Our conversation covered a lot of ground: his transition from pharma to biotech, the mindset shifts that come with startup life, and what it truly takes to build a company from scratch. We talked about science-to-business translation, how to recognise when a scientific idea is actually “company-ready”, and — of course — the joys (yes, that’s a joke) of fundraising and investor relations.
👉 If you’re curious about the dynamics of biotech startups — or you’re entertaining the idea of launching something of your own one day — this episode is for you.
